MNTL TEMA NEUROSCIENCE AND MENTAL HEALTH ETF
- 24.788
- +0.178+0.72%
Novo Nordisk Seeks to Block Compounded Victoza
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Regeneron Expands Eye Care Focus With Oxular Buyout
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Smart Money Is Betting Big In LLY Options
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Santa Claus Came Without Rallying the Troops | Live Stock
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
The 15.92% Average Gain in Inauguration Year: Will Trump's Second Term Echo the Trend?
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
17 Analysts Assess Biogen: What You Need To Know
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
Piper Sandler Downgrades Biogen to Neutral, Lowers Price Target to $138
Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.
New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.
Biogen Analyst Ratings
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
The three major US stock index futures rose collectively, and all seven giants were up in pre-market trading | Highlights for tonight.
① NVIDIA GB300 may be released in the second quarter of 2025; ② Eli Lilly and Co's weight loss drug tirzepatide has officially launched in China; ③ Apple announces price reductions.